Emerging Ovarian Targets Beyond Folate Receptor Alpha

Development of new antibody drug conjugates in ovarian cancer continues to expand beyond folate receptor alpha, and the faculty review why both target selection and trial design will be critical to future success. Earlier programs are described as cautionary examples when broad enrollment diluted potential benefit and made it harder to identify the patients most likely to respond. That experience has increased interest in more biomarker directed development strategies, along with closer attention to the biology of recurrent ovarian cancer. The discussion also compares evolving payload approaches, including topoisomerase based constructs that may offer broader activity through bystander effect, while potentially introducing different toxicity burdens. Ocular events, myelosuppression, gastrointestinal adverse effects, and treatment logistics all emerge as practical factors that may influence adoption once new agents reach clinical practice. The larger point is that strong response data alone may not be enough. Success will likely depend on matching the right target and payload to the right patient population while preserving tolerability in a heavily pretreated disease setting.